Rep. Gilbert Ray Cisneros, Jr. Sells Pfizer Inc. (NYSE:PFE) Stock

Representative Gilbert Ray Cisneros, Jr. (Democratic-California) recently sold shares of Pfizer Inc. (NYSE:PFE). In a filing disclosed on April 07th, the Representative disclosed that they had sold between $1,001 and $15,000 in Pfizer stock on March 13th. The trade occurred in the Representative’s “150 MAIN STREET TRUST > BANK OF AMERICA” account.

Representative Gilbert Ray Cisneros, Jr. also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of MACOM Technology Solutions (NASDAQ:MTSI) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of StandardAero (NYSE:SARO) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of FirstService (NASDAQ:FSV) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Charles Schwab (NYSE:SCHW) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Advanced Energy Industries (NASDAQ:AEIS) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Flex (NASDAQ:FLEX) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of LPL Financial (NASDAQ:LPLA) on 3/27/2026.
• Purchased $1,001 – $15,000 in shares of DoorDash (NASDAQ:DASH) on 3/27/2026.
• Sold $1,001 – $15,000 in shares of Viavi Solutions (NASDAQ:VIAV) on 3/27/2026.
• Purchased $15,001 – $50,000 in shares of Fabrinet (NYSE:FN) on 3/27/2026.

Pfizer Price Performance

Shares of Pfizer stock opened at $27.47 on Thursday. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $28.75. The stock has a market capitalization of $156.21 billion, a price-to-earnings ratio of 20.20 and a beta of 0.43. The company has a fifty day moving average of $27.17 and a 200-day moving average of $25.90. The company has a debt-to-equity ratio of 0.71, a quick ratio of 0.87 and a current ratio of 1.16.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. The company had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. During the same quarter in the prior year, the company earned $0.63 EPS. The firm’s revenue was down 1.2% on a year-over-year basis. Equities research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

Institutional Investors Weigh In On Pfizer

Several institutional investors have recently added to or reduced their stakes in the company. Stance Capital LLC raised its holdings in Pfizer by 26,746.0% in the 4th quarter. Stance Capital LLC now owns 26,846 shares of the biopharmaceutical company’s stock worth $668,000 after purchasing an additional 26,746 shares in the last quarter. Rockefeller Capital Management L.P. raised its holdings in Pfizer by 27.1% in the 4th quarter. Rockefeller Capital Management L.P. now owns 1,842,275 shares of the biopharmaceutical company’s stock worth $45,873,000 after purchasing an additional 392,913 shares in the last quarter. World Investment Advisors raised its holdings in Pfizer by 11.2% in the 4th quarter. World Investment Advisors now owns 397,952 shares of the biopharmaceutical company’s stock worth $9,909,000 after purchasing an additional 40,239 shares in the last quarter. Nalls Sherbakoff Group LLC bought a new position in Pfizer in the 4th quarter worth $92,000. Finally, DUTCH ASSET Corp bought a new position in Pfizer in the 4th quarter worth $237,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently issued reports on PFE shares. Guggenheim upped their price objective on shares of Pfizer from $35.00 to $36.00 and gave the company a “buy” rating in a research note on Tuesday, March 24th. Morgan Stanley set a $27.00 price objective on shares of Pfizer and gave the company a “positive” rating in a research note on Tuesday, March 17th. Royal Bank Of Canada assumed coverage on shares of Pfizer in a research report on Tuesday, February 24th. They set an “underperform” rating and a $25.00 price target for the company. Weiss Ratings reissued a “hold (c-)” rating on shares of Pfizer in a research report on Thursday, January 22nd. Finally, Wolfe Research set a $24.00 price target on shares of Pfizer and gave the company an “underperform” rating in a research report on Wednesday, December 17th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and three have assigned a Sell rating to the stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus target price of $28.19.

About Representative Cisneros

Gil Cisneros (Democratic Party) is a member of the U.S. House, representing California’s 31st Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027.

Cisneros (Democratic Party) is running for re-election to the U.S. House to represent California’s 31st Congressional District. He declared candidacy for the 2026 election.

Gil Cisneros served in the U.S. Navy as a supply officer from 1994 to 2004. Cisneros earned a bachelor’s degree in political science from George Washington University in 1994, a master’s in business administration from Regis University in 2002, and a master’s degree in urban education policy from Brown University in 2015. His career experience includes working as a logistics manager for Frito-Lay. In 2010, Cisneros won the lottery and became involved in activism and philanthropy, founding a scholarship program for local high school students. In 2021, President Joe Biden (D) appointed Cisneros as under secretary of defense for personnel and readiness.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.